Toka Alsulaim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Toka Alsulaim has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Abdullah Almutlaq
Rheumatology Division
1 shared publicationAicha Bouraoui
Southend University Hospital NHS Foundation Trust, Rheumatology University College London Hospitals, London, UK
1 shared publication- Corinne Fisher
Department of Rheumatology University College London Hospital, London, UK
1 shared publication - Debajit Sen
Department of Rheumatology University College London Hospital, London, UK
1 shared publication - Elham A AlQudari
Prince Mohammed Bin Abdulaziz Hosp, Dept Med, Riyadh, Saudi Arabia
1 shared publication Hala Khalil
Department of Biostatistics
1 shared publication
Latest Publications
- Open Access
- 25 April 2026
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1)
Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis
Background: Secondary drug failure to adalimumab remains a significant challenge in managing Juvenile Idiopathic Arthritis (JIA), with anti-adalimumab antibodies (ADA_ab) implicated as a potential mechanism. This study examines the relationship between ADA_ab formation and loss of response (LOR). Findings: In this retrospective, longitudinal study, a combination of conventional statistical methods and machine-learning algorithms were employed to investigate the association of adalimumab drug levels (ADA_drug) and ADA_ab, alongside clinical variables, on LOR among JIA patients treated between December 2016 and May 2024. LOR was defined as active disease. Among 184 patients, ADA_ab and ADA_drug emerged as the strongest predictors of LOR in random-forest analysis. In multiple logistic regression, higher ADA_ab levels were independently associated with increased risk of LOR (OR 1.18, 95% CI 1.08–1.29, p = 0.0003), while higher ADA_drug levels were associated with reduced risk (OR 0.81, 95% CI 0.68–0.95, p = 0.0103). An ADA_ab threshold of 69 AU/mL was associated with an eightfold increase in LOR (OR 8.04, 95% CI 2.8–26.1, p = 0.0002). Patients with high ADA_ab and undetectable ADA_drug had the highest risk of LOR (OR 28.24, 95% CI 7.11–111.63, p = 0.0001). Kaplan–Meier analysis demonstrated that 71% of patients with elevated ADA_ab experienced LOR within 12 months Conclusion: High ADA_ab levels are a significant predictor of LOR in JIA patients treated with adalimumab, particularly when coupled with low drug levels. We also report clinically meaningful one-year LOR rates. These findings support the use of therapeutic drug monitoring, which may help optimise treatment and improve long-term disease control.
- 25 April 2026
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1)
Open AccessAnti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis
Background: Secondary drug failure to adalimumab remains a significant challenge in managing Juvenile Idiopathic Arthritis (JIA), with anti-adalimumab antibodies (ADA_ab) implicated as a potential mechanism. This study examines the relationship between ADA_ab formation and loss of response (LOR). Findings: In this retrospective, longitudinal study, a combination of conventional statistical methods and machine-learning algorithms were employed to investigate the association of adalimumab drug levels (ADA_drug) and ADA_ab, alongside clinical variables, on LOR among JIA patients treated between December 2016 and May 2024. LOR was defined as active disease. Among 184 patients, ADA_ab and ADA_drug emerged as the strongest predictors of LOR in random-forest analysis. In multiple logistic regression, higher ADA_ab levels were independently associated with increased risk of LOR (OR 1.18, 95% CI 1.08–1.29, p = 0.0003), while higher ADA_drug levels were associated with reduced risk (OR 0.81, 95% CI 0.68–0.95, p = 0.0103). An ADA_ab threshold of 69 AU/mL was associated with an eightfold increase in LOR (OR 8.04, 95% CI 2.8–26.1, p = 0.0002). Patients with high ADA_ab and undetectable ADA_drug had the highest risk of LOR (OR 28.24, 95% CI 7.11–111.63, p = 0.0001). Kaplan–Meier analysis demonstrated that 71% of patients with elevated ADA_ab experienced LOR within 12 months Conclusion: High ADA_ab levels are a significant predictor of LOR in JIA patients treated with adalimumab, particularly when coupled with low drug levels. We also report clinically meaningful one-year LOR rates. These findings support the use of therapeutic drug monitoring, which may help optimise treatment and improve long-term disease control.
- Open Access
- 1 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25556
Weight Gain in Seropositive Rheumatoid Arthritis Patients Treated With Anti-tumor Necrosis Factor (TNF) Therapy
Rheumatoid arthritis and its treatment have different effects on weight gain. This study examined the effect of tumor necrosis factor (TNF) inhibitors on weight gain in patients with seropositive rheumatoid arthritis compared with non-TNF therapy and disease activity. A retrospective cohort study was conducted in Prince Mohammad bin Abdulaziz Hospital for all patients aged ≥ 18-year-old diagnosed with seropositive rheumatoid arthritis and started on TNF inhibitors or non-TNF biologics in outpatient clinics since 2015. Patients were excluded if they were pregnant, had an uncontrolled underlying metabolic disease, were post-bariatric, or had a history of malabsorption. We also excluded individuals on treatment for congestive heart failure or end-stage renal disease. A total of 116 patients with rheumatoid arthritis were reviewed between 2015 and 2019. Only 69 patients met the inclusion criteria (51 and 18) in the TNF-a (alpha) and non-TNF-a inhibitor groups, respectively. The weight change from pre-treatment to post-treatment showed an average increase of 1.2 kg (95% CI: -0.68-3.17) in the TNF-a inhibitor group while in the non- TNF-a inhibitor group, the average increase in weight was 2.67 kg (95% CI: -0.44-5.78). Over the period of two years, there was no statistical difference in weight gain in both groups or in relation to disease activity. The results of this study did not show a significant increase in weight gain in seropositive patients with rheumatoid arthritis who were treated with TNF or non-TNF inhibitors.
- 1 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e25556
Open AccessWeight Gain in Seropositive Rheumatoid Arthritis Patients Treated With Anti-tumor Necrosis Factor (TNF) Therapy
Rheumatoid arthritis and its treatment have different effects on weight gain. This study examined the effect of tumor necrosis factor (TNF) inhibitors on weight gain in patients with seropositive rheumatoid arthritis compared with non-TNF therapy and disease activity. A retrospective cohort study was conducted in Prince Mohammad bin Abdulaziz Hospital for all patients aged ≥ 18-year-old diagnosed with seropositive rheumatoid arthritis and started on TNF inhibitors or non-TNF biologics in outpatient clinics since 2015. Patients were excluded if they were pregnant, had an uncontrolled underlying metabolic disease, were post-bariatric, or had a history of malabsorption. We also excluded individuals on treatment for congestive heart failure or end-stage renal disease. A total of 116 patients with rheumatoid arthritis were reviewed between 2015 and 2019. Only 69 patients met the inclusion criteria (51 and 18) in the TNF-a (alpha) and non-TNF-a inhibitor groups, respectively. The weight change from pre-treatment to post-treatment showed an average increase of 1.2 kg (95% CI: -0.68-3.17) in the TNF-a inhibitor group while in the non- TNF-a inhibitor group, the average increase in weight was 2.67 kg (95% CI: -0.44-5.78). Over the period of two years, there was no statistical difference in weight gain in both groups or in relation to disease activity. The results of this study did not show a significant increase in weight gain in seropositive patients with rheumatoid arthritis who were treated with TNF or non-TNF inhibitors.
- Open Access
- 12 August 2021
- Published by Wiley in International Journal of Rheumatology
- Vol. 2021, 1-8
Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study
Objective. To study the effect of tocilizumab initiation on the lipid profile, in correlation to a composite of any cardiovascular events. Methods. A retrospective cohort study, using data from the King Faisal Specialist Hospital & Research Centre database, from January 2014 to December 2019. Patients with rheumatoid arthritis or juvenile idiopathic arthritis who were ≥18 years old, initiated either on tocilizumab or other biologic treatment (anti-TNFs or Rituximab), were included, with a follow-up interval duration at a minimum of 6–12 months up to 3-5 years. Any patient with established cardiovascular disease or aged Results. Only one cardiovascular mortality was reported in the tocilizumab group. Fifty percent of patients reached and in the tocilizumab group at 36 months in a shorter time period compared to controls (60 months), 0.001. There were no significant differences between groups for statin use (27% vs. 28%) However, there was a significantly higher mean dose of atorvastatin in the tocilizumab group compared to controls (20.6 mg vs. 16.6 mg, 0.03). Conclusion. There was a lack of evidence of increased cardiovascular risk in correlation to hyperlipidemia secondary to tocilizumab treatment.
- 12 August 2021
- Published by Wiley in International Journal of Rheumatology
- Vol. 2021, 1-8
Open AccessTocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study
Objective. To study the effect of tocilizumab initiation on the lipid profile, in correlation to a composite of any cardiovascular events. Methods. A retrospective cohort study, using data from the King Faisal Specialist Hospital & Research Centre database, from January 2014 to December 2019. Patients with rheumatoid arthritis or juvenile idiopathic arthritis who were ≥18 years old, initiated either on tocilizumab or other biologic treatment (anti-TNFs or Rituximab), were included, with a follow-up interval duration at a minimum of 6–12 months up to 3-5 years. Any patient with established cardiovascular disease or aged Results. Only one cardiovascular mortality was reported in the tocilizumab group. Fifty percent of patients reached and in the tocilizumab group at 36 months in a shorter time period compared to controls (60 months), 0.001. There were no significant differences between groups for statin use (27% vs. 28%) However, there was a significantly higher mean dose of atorvastatin in the tocilizumab group compared to controls (20.6 mg vs. 16.6 mg, 0.03). Conclusion. There was a lack of evidence of increased cardiovascular risk in correlation to hyperlipidemia secondary to tocilizumab treatment.
- Open Access
Anxiety and Depression in Patients with Pulmonary Hypertension and its Impact on Health-Related Quality of Life
Background Pulmonary Hypertension (PH) is a chronic progressive disease which affects quality of life. The prevalence of mood disorders in PH patients in Saudi Arabia is not known. Objectives This is a prospective observational study to investigate the prevalence of anxiety and depression in patients with pulmonary hypertension and its effect on health-related quality of life (HRQoL). Methods Forty-two PH patients were evaluated for mood disorders by using Hospital Anxiety and Depression Scale (HADS) and health related quality of life was assessed with The Short Form 36 (SF-36) Health Survey questionnaire. Results Mean age for the cohort was 42.8 (±13.3) years and 31(73%) were female. Mean pulmonary artery pressure was 46.4 (± 15) mm Hg and 25 (60%) patients had severe PH (mPAP ≥45 mmHg). Thirty-eight (90%) patients were in World Health Organization Functional Class (WHO-FC) II/III and 5 (10%) class IV. HADS anxiety and depression score was positive (11-21) in 4 (10%) and 6 (14%) patients respectively. Presence of anxiety and/or depression affected HRQoL. Conclusion Prevalence of anxiety and depression in PH patients in Saudi Arabia is low (10% and 14% respectively) compared to published studies. The low prevalence may be explained by cultural and social differences and strong family support.
Open AccessAnxiety and Depression in Patients with Pulmonary Hypertension and its Impact on Health-Related Quality of Life
Background Pulmonary Hypertension (PH) is a chronic progressive disease which affects quality of life. The prevalence of mood disorders in PH patients in Saudi Arabia is not known. Objectives This is a prospective observational study to investigate the prevalence of anxiety and depression in patients with pulmonary hypertension and its effect on health-related quality of life (HRQoL). Methods Forty-two PH patients were evaluated for mood disorders by using Hospital Anxiety and Depression Scale (HADS) and health related quality of life was assessed with The Short Form 36 (SF-36) Health Survey questionnaire. Results Mean age for the cohort was 42.8 (±13.3) years and 31(73%) were female. Mean pulmonary artery pressure was 46.4 (± 15) mm Hg and 25 (60%) patients had severe PH (mPAP ≥45 mmHg). Thirty-eight (90%) patients were in World Health Organization Functional Class (WHO-FC) II/III and 5 (10%) class IV. HADS anxiety and depression score was positive (11-21) in 4 (10%) and 6 (14%) patients respectively. Presence of anxiety and/or depression affected HRQoL. Conclusion Prevalence of anxiety and depression in PH patients in Saudi Arabia is low (10% and 14% respectively) compared to published studies. The low prevalence may be explained by cultural and social differences and strong family support.